RecruitingNot ApplicableNCT06328062

Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA

Comparison Efficacy of Mirogabalin and Pregabalin in Total Knee Arthroplasty. a Randomized Controlled Trial


Sponsor

Thammasat University Hospital

Enrollment

80 participants

Start Date

Apr 1, 2024

Study Type

INTERVENTIONAL

Summary

The goal of this RCT is to compare efficacy between mirogabalin and pregabalin in pain reducing after unilateral primary total knee arthroplasty. The main question\[s\] it aims to answer are: • Does mirogabalin have better pain reduction than pregabalin after unilateral primary total knee arthroplasty. Participants will randomized to mirogabalin or pregabalin group and will take the drug for 6 weeks after TKA. Researchers will compare to pregabalin group to see pain and functional outcomes after TKA.


Eligibility

Min Age: 50 YearsMax Age: 85 Years

Inclusion Criteria3

  • Age 50-85 years old
  • Unilateral primary osteoarthritis undergoing primary TKA
  • ASA I-III

Exclusion Criteria6

  • GFR \<60
  • Allergy to drug in this study
  • Cannot underwent spinal anesthesia and adductor canal block
  • Taking gabapentinoid within 3 months before surgery
  • History of previous knee surgery
  • Severe liver disease

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMirogabalin

Participants will receive 5 mg of mirogabalin, taken as half a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.

DRUGPregabalin

Participants will receive 50 mg of pregabalin, taken as a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.


Locations(1)

Thammasat University Hospital

Khlong Luang, Changwat Pathum Thani, Thailand

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06328062